Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

The NHS is rolling out a one-minute immunotherapy injection for over a dozen types of cancer, including lung, breast, and cervical cancer. This new injectable form of pembrolizumab (Keytruda) can ...

The NHS has begun rolling out a subcutaneous form of pembrolizumab (Keytruda, Merck) that can cut the time patients spend receiving the immunotherapy by up to 90%, reducing a process that previously ...

Health Minister Mike Nesbitt has confirmed that a key injectable cancer drug which can be used to treat multiple cancers is being used in three of Northern Ireland's five health trusts. Pembrolizumab ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

The NHS is introducing a one-minute jab that could help tens of thousands of cancer patients. Around 14,000 people in England start using pembrolizumab (Keytruda) via a drip each year, and most are ...

The drug is normally received by patients through a drip which can take more than an hour in hospital, but injectables are quicker and less intrusive Health Minister Mike Nesbitt has confirmed that a ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, ...

A leading cancer researcher has said that Northern Ireland patients should not be left behind in a "postcode lottery" as a new injectable cancer drug is rolled out across other parts of the UK. The ...

The Department of Health said it is "aware" of the jab and is "exploring" how it can be made available to patients in Northern Ireland "as soon as possible" A leading cancer researcher has said that ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...